- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Concluding Thoughts on Ph+ ALL Treatment
Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.
EP: 1.Overview of Characteristics Unique to Ph+ ALL
EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL
EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life
EP: 4.Screening and Diagnosing of Ph+ ALL in Adults
EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management
EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL
EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients
EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients
EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care
EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL
EP: 11.Disparities in Access to Care for Ph+ ALL patients
EP: 12.The Future of Ph+ ALL Treatments
EP: 13.Concluding Thoughts on Ph+ ALL Treatment
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
In conclusion, Dr Abbas stressed engaging community practices more in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) care while ensuring specialist leadership and optimal up-front therapy access. Dr Jabbour highlighted immense survival gains from 10% to 90% in recent years, with cures becoming reality now—not just ideals for the future. Equity in access to best available treatments remains vital. Dr McCloskey advised rethinking outdated potent toxicity perceptions given new safety data enabling more appropriate patient selection. Robust measurable residual disease monitoring must inform Ph+ ALL management everywhere. Dr Ebot-Tar discussed payers balancing innovation support, value demonstration to stakeholders, and personalized care. Ongoing collaboration between specialties and health plans can continue progress.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
